

Title (en)

A GENE THERAPY SYSTEM AND METHOD USING ALPHA-MSH AND ITS DERIVATIVES

Title (de)

EIN GENTHERAPIE-SYSTEM UND EIN VERFAHREN, DAS ALPHA-MSH UND SEINE DERIVATE VERWENDET

Title (fr)

SYSTEME ET PROCEDE DE THERAPIE GENIQUE UTILISANT ALPHA-MSH ET SES DERIVES

Publication

EP 1280409 A4 20040519 (EN)

Application

EP 01930932 A 20010427

Priority

- US 0113826 W 20010427
- US 20028700 P 20000428

Abstract (en)

[origin: WO0182699A1] Disclosed in this specification is the use alpha-MSH and/or its derivatives as an adjunct to gene therapy. In one aspect, the gene therapy vector includes nucleic acids that expresses alpha-MSH and/or its derivatives. Inflammatory or immune response gene promoter may control the expression of alpha-MSH and/or its derivatives. The sequences may also be expressed together with a therapeutic gene using an internal ribosomal entry site sequence. In another aspect, pharmacologically effective amount of alpha-MSH and/or its derivatives may be administered before, after, or concurrently with the gene therapy vector carrying the appropriate gene.

IPC 1-7

A01N 43/04; A61K 31/70; C12N 15/00; C12N 15/09; C12N 15/74; C12N 15/85; C12N 15/87

IPC 8 full level

A61K 35/76 (2006.01); **A61K 38/22** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **A61P 7/04** (2006.01); **A61P 35/00** (2006.01);
A61P 43/00 (2006.01); **C12N 15/09** (2006.01)

CPC (source: EP)

A61K 47/64 (2017.07); **A61K 48/00** (2013.01); **A61P 7/04** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

- [PX] WO 0033658 A1 20000615 - ELEANOR ROOSEVELT INST [US], et al
- [X] WO 0042856 A1 20000727 - SCHEPENS EYE RES INST [US], et al
- [E] WO 0206316 A2 20020124 - ZYCOS INC [US], et al
- [X] HILTZ M E ET AL: "ANTI-INFLAMMATORY ACTIVITY OF ALPHA-MSH(11-13) ANALOGS: INFLUENCES OF ALTERATION IN STEREOCHEMISTRY", PEPTIDES, ELMSFORD, US, vol. 12, 1991, pages 767 - 771, XP000570459, ISSN: 0196-9781
- [X] CATANIA ANNA ET AL: "The neuropeptide alpha-melanocyte-stimulating hormone: A key component of neuroimmunomodulation", NEUROIMMUNOMODULATION, vol. 1, no. 2, 1994, pages 93 - 99, XP009028112, ISSN: 1021-7401
- [X] DELGADO HERNANDEZ RENE ET AL: "Inhibition of systemic inflammation by central action of the neuropeptide alpha-melanocyte-stimulating hormone", NEUROIMMUNOMODULATION, vol. 6, no. 3, May 1999 (1999-05-01), pages 187 - 192, XP009028113, ISSN: 1021-7401
- [X] CUTULI M ET AL: "ANTIMICROBIAL EFFECTS OF ALPHA-MSH PEPTIDES", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 67, February 2000 (2000-02-01), pages 233 - 239, XP002931058, ISSN: 0741-5400
- See references of WO 0182699A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0182699 A1 20011108; AU 5742001 A 20011112; CA 2406755 A1 20011108; CN 1429073 A 20030709; EP 1280409 A1 20030205;
EP 1280409 A4 20040519; JP 2004509065 A 20040325

DOCDB simple family (application)

US 0113826 W 20010427; AU 5742001 A 20010427; CA 2406755 A 20010427; CN 01808571 A 20010427; EP 01930932 A 20010427;
JP 2001579591 A 20010427